Advertisement

Table of Contents

In This Issue

  • In This Issue
    In This Issue
    Cancer Discov October 1 2020 10 (10) 1426-1430; DOI:10.1158/2159-8290.CD-ITI10-10

In the Spotlight

Science in Society

Mini Review

Research Briefs

  • Research Briefs | Free Article
    Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
    David J. Pinato, Alberto Zambelli, Juan Aguilar-Company, Mark Bower, Christopher C.T. Sng, Ramon Salazar, Alexia Bertuzzi, Joan Brunet, Ricard Mesia, Elia Seguí, Federica Biello, Daniele Generali, Salvatore Grisanti, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Nadia Harbeck, Bruno Vincenzi, Rossella Bertulli, Diego Ottaviani, Anna Carbó, Riccardo Bruna, Sarah Benafif, Andrea Marrari, Rachel Wuerstlein, M. Carmen Carmona-Garcia, Neha Chopra, Carlo Tondini, Oriol Mirallas, Valeria Tovazzi, Marta Betti, Salvatore Provenzano, Vittoria Fotia, Claudia Andrea Cruz, Alessia Dalla Pria, Francesca D'Avanzo, Joanne S. Evans, Nadia Saoudi-Gonzalez, Eudald Felip, Myria Galazi, Isabel Garcia-Fructuoso, Alvin J.X. Lee, Thomas Newsom-Davis, Andrea Patriarca, David García-Illescas, Roxana Reyes, Palma Dileo, Rachel Sharkey, Yien Ning Sophia Wong, Daniela Ferrante, Javier Marco-Hernández, Anna Sureda, Clara Maluquer, Isabel Ruiz-Camps, Gianluca Gaidano, Lorenza Rimassa, Lorenzo Chiudinelli, Macarena Izuzquiza, Alba Cabirta, Michela Franchi, Armando Santoro, Aleix Prat, Josep Tabernero and Alessandra Gennari
    Cancer Discov October 1 2020 10 (10) 1465-1474; DOI:10.1158/2159-8290.CD-20-0773

    Higher risk of death from COVID-19 among patients with cancer was correlated with male sex, greater age, presence of multiple comorbidities, advanced-stage disease, and active disease; there was no association between risk and anticancer treatment.

  • Research Briefs
    Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
    Stephen J. Pettitt, Jessica R. Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew N.J. Tutt and Christopher J. Lord
    Cancer Discov October 1 2020 10 (10) 1475-1488; DOI:10.1158/2159-8290.CD-19-1485

    Reversion mutations that cause resistance of initially homologous recombination–deficient tumors to PARP inhibitors and platinum-based chemotherapies often affect BRCA1/2 and may lead to susceptibility to immunotherapy.

  • Research Briefs
    Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
    Adam Pennycuick, Vitor H. Teixeira, Khalid AbdulJabbar, Shan E. Ahmed Raza, Tom Lund, Ayse U. Akarca, Rachel Rosenthal, Lukas Kalinke, Deepak P. Chandrasekharan, Christodoulos P. Pipinikas, Henry Lee-Six, Robert E. Hynds, Kate H.C. Gowers, Jake Y. Henry, Fraser R. Millar, Yeman B. Hagos, Celine Denais, Mary Falzon, David A. Moore, Sophia Antoniou, Pascal F. Durrenberger, Andrew J. Furness, Bernadette Carroll, Claire Marceaux, Marie-Liesse Asselin-Labat, William Larson, Courtney Betts, Lisa M. Coussens, Ricky M. Thakrar, Jeremy George, Charles Swanton, Christina Thirlwell, Peter J. Campbell, Teresa Marafioti, Yinyin Yuan, Sergio A. Quezada, Nicholas McGranahan and Sam M. Janes
    Cancer Discov October 1 2020 10 (10) 1489-1499; DOI:10.1158/2159-8290.CD-19-1366

    Poor CD8+ T-cell infiltration, defective antigen presentation, and aberrant upregulation of CCL27 and CCR10 and downregulation of TNFSF9 (all immune system genes) were associated with progression of preinvasive lung carcinoma in situ.

  • Research Briefs
    Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
    Sheng F. Cai, S. Haihua Chu, Aaron D. Goldberg, Salma Parvin, Richard P. Koche, Jacob L. Glass, Eytan M. Stein, Martin S. Tallman, Filiz Sen, Christopher A. Famulare, Monica Cusan, Chun-Hao Huang, Chun-Wei Chen, Lihua Zou, Keith B. Cordner, Nicole L. DelGaudio, Vidushi Durani, Mitali Kini, Madison Rex, Helen S. Tian, Johannes Zuber, Timour Baslan, Scott W. Lowe, Hugh Y. Rienhoff Jr, Anthony Letai, Ross L. Levine and Scott A. Armstrong
    Cancer Discov October 1 2020 10 (10) 1500-1513; DOI:10.1158/2159-8290.CD-19-1469

    Compared with granulocyte–monocyte progenitor cell–derived acute myeloid leukemia, hematopoietic stem cell–derived leukemia was more resistant to LSD1 inhibition and apoptosis, but resistance was reversed by venetoclax.

Research Articles

  • Research Articles | AuthorChoice
    Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
    Donna R. Rivera, Solange Peters, Orestis A. Panagiotou, Dimpy P. Shah, Nicole M. Kuderer, Chih-Yuan Hsu, Samuel M. Rubinstein, Brendan J. Lee, Toni K. Choueiri, Gilberto de Lima Lopes Jr., Petros Grivas, Corrie A. Painter, Brian I. Rini, Michael A. Thompson, Jonathan Arcobello, Ziad Bakouny, Deborah B. Doroshow, Pamela C. Egan, Dimitrios Farmakiotis, Leslie A. Fecher, Christopher R. Friese, Matthew D. Galsky, Sanjay Goel, Shilpa Gupta, Thorvardur R. Halfdanarson, Balazs Halmos, Jessica E. Hawley, Ali Raza Khaki, Christopher A. Lemmon, Sanjay Mishra, Adam J. Olszewski, Nathan A. Pennell, Matthew M. Puc, Sanjay G. Revankar, Lidia Schapira, Andrew Schmidt, Gary K. Schwartz, Sumit A. Shah, Julie T. Wu, Zhuoer Xie, Albert C. Yeh, Huili Zhu, Yu Shyr, Gary H. Lyman and Jeremy L. Warner; on behalf of the COVID-19 and Cancer Consortium
    Cancer Discov October 1 2020 10 (10) 1514-1527; DOI:10.1158/2159-8290.CD-20-0941

    In a large observational study in patients with COVID-19 and cancer, survival was not significantly influenced by receipt of COVID-19 treatments, except hydroxychloroquine plus any other treatment, which was associated with reduced survival.

  • Research Articles | AuthorChoice
    Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non–BRCA1/2-Mutant Cancers
    Timothy A. Yap, Rebecca Kristeleit, Vasiliki Michalarea, Stephen J. Pettitt, Joline S.J. Lim, Suzanne Carreira, Desamparados Roda, Rowan Miller, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava Rodrigues, Sarah Ward, Ruth Matthews, Mona Parmar, Alison Turner, Nina Tunariu, Neha Chopra, Heidrun Gevensleben, Nicholas C. Turner, Ruth Ruddle, Florence I. Raynaud, Shaun Decordova, Karen E. Swales, Laura Finneran, Emma Hall, Paul Rugman, Justin P.O. Lindemann, Andrew Foxley, Christopher J. Lord, Udai Banerji, Ruth Plummer, Bristi Basu, Juanita S. Lopez, Yvette Drew and Johann S. de Bono
    Cancer Discov October 1 2020 10 (10) 1528-1543; DOI:10.1158/2159-8290.CD-20-0163

    In a phase I trial of patients with advanced solid tumors, combination treatment with the PARP inhibitor olaparib and the AKT inhibitor capivasertib showed early signs of efficacy, supporting preclinical observations of synergy.

  • Research Articles
    Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia
    Nesrine Aroua, Emeline Boet, Margherita Ghisi, Marie-Laure Nicolau-Travers, Estelle Saland, Ryan Gwilliam, Fabienne de Toni, Mohsen Hosseini, Pierre-Luc Mouchel, Thomas Farge, Claudie Bosc, Lucille Stuani, Marie Sabatier, Fetta Mazed, Clément Larrue, Latifa Jarrou, Sarah Gandarillas, Massimiliano Bardotti, Muriel Picard, Charlotte Syrykh, Camille Laurent, Mathilde Gotanègre, Nathalie Bonnefoy, Floriant Bellvert, Jean-Charles Portais, Nathalie Nicot, Francisco Azuaje, Tony Kaoma, Carine Joffre, Jérome Tamburini, Christian Récher, François Vergez and Jean-Emmanuel Sarry
    Cancer Discov October 1 2020 10 (10) 1544-1565; DOI:10.1158/2159-8290.CD-19-1008

    CD39-expressing acute myeloid leukemia cells expanded after cytarabine treatment and activated the cell survival–promoting mitochondrial stress response, leading to relapse with chemotherapy-resistant disease.

  • Research Articles | AuthorChoice
    Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes
    Koji Miyabayashi, Lindsey A. Baker, Astrid Deschênes, Benno Traub, Giuseppina Caligiuri, Dennis Plenker, Brinda Alagesan, Pascal Belleau, Siran Li, Jude Kendall, Gun Ho Jang, Risa Karakida Kawaguchi, Tim D.D. Somerville, Hervé Tiriac, Chang-Il Hwang, Richard A. Burkhart, Nicholas J. Roberts, Laura D. Wood, Ralph H. Hruban, Jesse Gillis, Alexander Krasnitz, Christopher R. Vakoc, Michael Wigler, Faiyaz Notta, Steven Gallinger, Youngkyu Park and David A. Tuveson
    Cancer Discov October 1 2020 10 (10) 1566-1589; DOI:10.1158/2159-8290.CD-20-0133

    A new mouse model enabled ascertainment of molecular details of the two pancreatic ductal adenocarcinoma subtypes, revealing that the transition from a slow-growing to a fast-growing tumor is marked by activation of KRAS signaling genes.

  • Research Articles
    Lineage Reversion Drives WNT Independence in Intestinal Cancer
    Teng Han, Sukanya Goswami, Yang Hu, Fanying Tang, Maria Paz Zafra, Charles Murphy, Zhen Cao, John T. Poirier, Ekta Khurana, Olivier Elemento, Jaclyn F. Hechtman, Karuna Ganesh, Rona Yaeger and Lukas E. Dow
    Cancer Discov October 1 2020 10 (10) 1590-1609; DOI:10.1158/2159-8290.CD-19-1536

    Colorectal cancer organoids escaped dependence on WNT signaling via a combination of cancer-associated mutations and priming by TGFβ, abundant in the tumor microenvironment, indicating a possible mechanism of resistance to PORCN inhibitors.

News in Brief

News in Depth

Research Watch

Back to top

Jump to

Advertisement